

Catalent

Investors Conference Call

Catalent Pharma Solutions
February 13, 2009

Reliable Solutions. Inspired Results.™



Disclaimer Statement

Forward Looking Statements

This presentation and release contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate”, “intend”, “estimate”, “plan”, “project”, “foresee”, “likely”, “may”, “will”, “would” or other words or phrases with similar meanings. Similarly, statements that describe our objectives, plans or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent Pharma Solutions’ expectations and projections. Some of the factors that could cause actual results to differ include, but are not limited to, the following: general industry conditions and competition; product or other liability risk inherent in the design, development, manufacture and marketing of our offerings; inability to enhance our existing or introduce new technology or services in a timely manner; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; and our substantial debt and debt service requirements that restrict our operating and financial flexibility and impose significant interest and financial costs. For a more detailed discussion of these and other factors, see the information under the caption “Risk Factors” in our Annual Report on Form 10K dated June 30, 2008, filed with the Securities and Exchange Commission on September 29, 2008. All forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent Pharma Solutions does not undertake to update any forward- looking statements as a result of new information or future events or developments unless required by law.

Non-GAAP Financial Matters

In addition to disclosing financial results that are determined in accordance with US GAAP, Catalent discloses EBITDA and Adjusted EBITDA, which are non-GAAP measures. You should not consider EBITDA or Adjusted EBITDA as an alternative to operating or net earnings, determined in accordance with US GAAP, as an indicator of Catalent's operating performance, or as an alternative to cash flows from operating activities, determined in accordance with US GAAP, as an indicator of cash flows, or as a measure of liquidity. EBITDA is calculated by the sum of earnings before interest, taxes, depreciation and amortization.

The Company's credit facilities and the indentures governing the outstanding notes have certain covenants that use ratios utilizing a measure referred to as Adjusted EBITDA. The supplementary adjustments to EBITDA to derive Adjusted EBITDA may not be in accordance with current SEC practices or the rules and regulations adopted by the SEC that apply to periodic reports filed under the Securities Exchange Act of 1934. Accordingly, the SEC may require that Adjusted EBITDA be presented differently in filings that may be made with the SEC than as presented in this release, or not be presented at all. The most directly comparable US GAAP measure to EBITDA and Adjusted EBITDA is net earnings (loss). Included in this release is a reconciliation of net earnings (loss) to EBITDA and to Adjusted EBITDA.

Agenda

- **Second Quarter Highlights**
- **Business Update**
- **Q2 and Six Month Financial Performance**
- **Adjusted EBITDA**
- **Cash Flow**
- **Q&A**

Second Quarter Highlights

- **Consolidated financial performance below prior year**
- **Oral Technologies: Zydis[®] capacity utilization; growth in pharmaceutical softgel**
- **Packaging: North American commercial packaging and printed components; Europe a bright spot**
- **Sterile Technologies: analytical science services; continued growth in sterile injectibles**
- **Somerset Zydis facility received first FDA product approval**
- **Containing controllable expenditures**

Business Update – Oral Technologies

- **New Zydis line in Somerset NJ received FDA approval in January. Commercial production to commence Q3 FY2009**
- **Zydis expansion in Swindon UK of two new high output lines progressing. Product validation on-going for first new line, equipment qualification has begun on second**
- **Rx softgel business continues to perform ahead of expectations, with strong demand for several high-volume brand products**
- **Sales of nutritional and certain other consumer health softgel products remains weak due to lower consumer demand in most markets**

Business Update – Sterile Technologies

- **Slow first half for analytical science services due to project cancellations and slowdown in development spending. Cost containment measures enacted and continuing**
- **Sterile injectibles profitability up strongly; ~30% ahead of prior year. FDA product approval at Brussels PFS facility will help to grow an already strong pipeline of opportunities**
- **Blow-fill-seal performance level with prior year; strong pipeline of new projects for future growth including recent launch of SECURE-VIAL™ blow-fill-seal vial**
- **Making encouraging progress in our biologics formulation and manufacturing business with continuing demand for our GPEx technology and for small scale manufacturing**

Business Update – Packaging Services

- **Commercial packaging: sales and profitability trend stabilizing with positive quote activity in the quarter**
- **Printed components: headcount reduction and efficiency gains executed; more to come**
- **Europe: matching prior year performance overall, with demand for Clinical Supplies exceeding prior year performance during the second quarter**
- **Customer satisfaction metrics remain a priority with positive trends continuing**
- **Additional senior leadership team improvements**

FY2009 Q2 by Segment

(\$ millions)	Three Months Ended December 31, 2008	Three Months Ended December 31, 2007	Increase/(Decrease)		Excluding FX Increase/(Decrease)		
			\$	%	\$	%	
Oral Technologies							
Net Revenue	221.6	256.9	(35.3)	-13.7%	(13.4)	-5.2%	
Segment EBITDA	50.5	50.5	(0.1)	-0.1%	3.2	6.3%	
Sterile Technologies							
Net Revenue	67.6	72.5	(4.9)	-6.8%	(2.4)	-3.3%	
Segment EBITDA	5.8	8.7	(2.9)	-33.0%	(2.7)	-31.1%	
Packaging Services							
Net Revenue	117.9	143.7	(25.8)	-17.9%	(16.8)	-11.7%	
Segment EBITDA	7.9	19.7	(11.8)	-59.8%	(10.1)	-51.1%	
Revenue Elimination	(12.6)	(12.2)	(0.4)	3.0%	(0.2)	1.6%	
Other EBITDA	(65.8)	(53.3)	(12.6)	*	(31.0)	*	
Combined Total							
Net Revenue	394.5	460.9	(66.5)	-14.4%	(32.7)	-7.1%	
EBITDA	(1.6)	25.6	(27.2)	*	(40.6)	*	
(from continuing operations)							

* % not meaningful

FY2009 YTD by Segment

(\$ millions)	Six Months	Six Months	Increase/(Decrease)		Excluding FX	
	Ended	Ended			Increase/(Decrease)	
	December 31, 2008	December 31, 2007	\$	%	\$	%
Oral Technologies						
Net Revenue	458.8	492.1	(33.2)	-6.8%	(17.5)	-3.6%
Segment EBITDA	94.6	99.9	(5.3)	-5.3%	(2.5)	-2.5%
Sterile Technologies						
Net Revenue	142.3	140.1	2.2	1.6%	1.4	1.0%
Segment EBITDA	15.0	15.2	(0.2)	-1.3%	(0.8)	-5.2%
Packaging Services						
Net Revenue	234.3	285.4	(51.1)	-17.9%	(42.9)	-15.0%
Segment EBITDA	15.2	40.5	(25.3)	-62.5%	(23.7)	-58.5%
Revenue Elimination	(23.8)	(21.6)	(2.2)	10.2%	(1.4)	6.2%
Other EBITDA	(25.4)	(110.6)	85.2	*	67.2	*
Combined Total						
Net Revenue	811.6	896.0	(84.4)	-9.4%	(60.5)	-6.7%
EBITDA	99.4	45.0	54.4	*	40.2	*
(from continuing operations)						

* % not meaningful

Operating Earnings to EBITDA

(\$ Millions)	Quarters Ended				LTM	Quarter Ended	LTM
	Dec 31, 2007	Mar 31, 2008	Jun 30, 2008	Sep 30, 2008	Sep 30, 2008	Dec 31, 2008	Dec 31, 2008
Income / (Loss) from continuing operations	(39.2)	(65.7)	(318.9)	21.8	(402.0)	(96.2)	(459.0)
Interest Expense, net	52.0	51.7	48.2	48.3	200.2	49.9	198.1
Income tax benefit	(27.7)	(26.4)	10.2	(7.3)	(51.2)	6.9	(16.6)
Depreciation and Amortization	40.7	42.0	35.8	38.2	156.7	37.8	153.8
EBITDA	25.8	1.6	(224.7)	101.0	(96.3)	(1.6)	(123.7)

LTM EBITDA Adjustments

(\$ millions)					LTM	Quarter	LTM
	Dec 31, 2007	Mar 31, 2008	Jun 30, 2008	Sep 30, 2008	Sep 30, 2008	Ended Dec 31, 2008	Dec 31, 2008
EBITDA	25.8	1.6	(224.7)	101.0	(96.3)	(1.6)	(123.7)
FAS 123R Equity Expense	2.2	3.0	1.2	1.4	7.8	1.0	6.5
Impairment charges and (gain)/loss on sale of assets	-	-	316.6	0.1	316.7	(0.1)	316.5
Purchase accounting, restructuring and other special items	9.0	7.4	3.0	2.6	22.0	1.9	14.9
Other non-recurring/one time items (Sterile Facility Start Up, non cash adjustments)	10.4	(2.6)	(1.7)	3.5	9.6	1.1	0.3
Unrealized fx loss (included in other,net)	33.9	72.1	8.6	(59.2)	55.4	63.9	85.4
Other (Minority interest expense, Sponsor's fee, severance, franchise taxes)	3.8	5.6	7.0	4.6	21.0	2.2	19.4
Disposition adjustments	2.7	(0.1)	0.2	-	2.8	-	0.1
Subtotal	87.8	87.0	110.2	54.0	339.0	68.4	319.4
Estimated cost savings					1.5		0.7
Adjusted EBITDA					340.5		320.1

FY2009 YTD Cash Flow

(\$ millions)	<u>Continuing</u>	<u>Discontinued</u>	<u>Total</u>
Net cash provided by/(used in) operations	(10.4)	2.1	(8.3)
Additions PP&E, net	(27.7)	(0.8)	(28.5)
Financing activities			60.8
FX on net cash			(10.1)
Increase/(Decrease) in cash			<u>13.9</u>
Cash at beginning of period			72.4
Cash at end of period			86.3
Items of note:			
Net cash cycle working capital increase			(4.6)
Cash interest			(92.6)
Cash taxes			(8.2)
Revolver at 12/31/08			79.0
Net Debt at 12/31/08			2,321.2



Catalent™

The logo features the word 'Catalent' in a bold, blue, sans-serif font. To the right of the text are three diagonal lines: a dark blue line pointing up and to the right, a purple line pointing down and to the right, and a purple line pointing up and to the right. The background includes decorative elements: a dark blue horizontal line on the left, a purple horizontal line on the right, and a green-to-blue gradient bar at the bottom.

Reliable Solutions. Inspired Results.™